Why Mounjaro (Tirzepatide) Causes Pancreatitis: The Mechanism Explained

What the Mounjaro label says about pancreatitis

Mounjaro is a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors [1]. Its label lists acute pancreatitis under warnings and precautions and states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro [1]. It tells clinicians to observe patients for signs and symptoms, which may include persistent or severe abdominal pain sometimes radiating to the back, with or without nausea or vomiting, and says to discontinue Mounjaro and initiate appropriate management if pancreatitis is suspected [1].

The pancreatitis warning in section 5.2 gives no account of how the drug might trigger the event [1].

Do trials show an increased risk?

A meta-analysis of nine randomized trials with 9,871 participants, 6,828 on tirzepatide and 3,043 controls, found no significant association between tirzepatide and pancreatitis: risk ratio 1.46, 95% CI 0.59 to 3.61 [2]. The interval is wide, running from 0.59 to 3.61, so a modest increase is not ruled out; the review concluded that tirzepatide appears safe regarding pancreatitis but flagged gallbladder or biliary disease as needing attention [2].

A separate meta-analysis of 21 trials and 99,599 patients, covering eight GLP-1 receptor agonists including tirzepatide, found no difference in pancreatitis between GLP-1 receptor agonists and controls [3]. Observational studies in people with type 2 diabetes or obesity have shown frequent gastrointestinal effects but no clear increase in severe events such as pancreatitis or pancreatic cancer [4].

Does the dual GIP and GLP-1 action change the risk?

Tirzepatide activates both GIP and GLP-1 receptors [1]; semaglutide is a selective GLP-1 receptor agonist [5]. Whether that difference matters for pancreatitis is not settled by the trial that compared the two drugs. SURPASS-2 compared tirzepatide with semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks, and its primary endpoint was change in HbA1c, not pancreatitis [5].

What animal data do and do not show

In a 75-day study of 20 rats, 10 received exendin-4 (exenatide), a GLP-1 receptor agonist, and 10 were controls [6]. The treated rats had more pancreatic acinar inflammation, more pyknotic nuclei and higher serum lipase than controls, and the authors wrote that this raises concern about inducing acute pancreatitis in humans receiving incretin therapy [6]. It is a small rat study of a different drug.

What symptoms does the label link to pancreatitis?

The label lists persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1]. Nausea is also a common adverse reaction: in the pooled placebo-controlled adult trials, nausea occurred in 12% to 18% of Mounjaro-treated patients versus 4% on placebo [1]. Nausea alone is common; the label's pancreatitis description centres on persistent or severe abdominal pain [1].

The same label separately warns about acute gallbladder disease, including cholelithiasis, biliary colic and cholecystectomy, reported by 0.6% of Mounjaro-treated adults versus 0% on placebo in adult placebo-controlled trials [1]. It says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

What about the starting dose?

The label warns about acute pancreatitis without limiting the warning to a particular dose; 2.5 mg once weekly is the starting dose and 15 mg once weekly is the maximum adult dose [1]. We found no published analysis that sets a dose threshold for pancreatitis.